Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

There are many possible explanations for that, including side effects and the drug’s cost. According to a KFF analysis, the list price for GLP-1 drugs can range between $936 and $1,349 before ...

GLP-1 drugs, or GLP-1 receptor agonists ... has not added Saxenda to its essential medicines list. Exenatide, like semaglutide, increases the amount of GLP-1 hormones produced by the body. These ...

the evolution of the markets in which Allurion competes and the rise of GLP-1 drugs, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements ...

Consequently, people using GLP-1 medications for weight loss may litigate ... For instance, at the start of 2024, the US list prices of Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly) increased ...

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...

At the J.P. Morgan Health Care conference this week in San Francisco, drugmakers had their sights set on the next generation of GLP-1 medications, alternatives, and a growing list of indications ...